Expression of SOX-2 in breast invasive carcinoma of no special type and its clinical and pathological significance

doi:10.16150/j.1671-2870.2018.06.014

Abstract

Abstract: Objective: To study the expression of SOX-2 (sex determining region Y-box) in breast invasive carcinoma of no special type (ICNST) and analyze its significance and relationship with ER, PR, Her-2, Ki-67 and clinicopathological features. Methods: Normal breast tissue specimens (30 cases) and ICNST specimens of 179 patients and their complete clinical and pathological data during the period from January 2005 to December 2012 at Nanjing General Hospital of Nanjing Military Command were collected. The clinicopathological features included age, menstrual status, clinical stage, recurrence, metastasis, death, and expressions of ER, PR, Ki-67 and Her-2. The expressions of SOX-2, ER, PR, Ki-67 and Her-2 were detected by immunohistochemistry. Analysis of the clinicopathological features in association with SOX-2 expression was performed. Results: The expression of SOX-2 was significantly higher in ICNST cancer tissues than that in normal breast tissue (P<0.05). SOX-2 expression in ICNST was correlated with recurrence, lymph node metastasis and clinical staging (P<0.05), while had no significant correlation with histological grade, age, menopausal status, tumor size, ER, PR, Her-2, Ki-67 and molecular typing. Kaplan-Meier analysis showed that disease free survival time and total survival time in SOX-2 positive group were shorter than that in SOX-2 negative group (P<0.05). COX analysis revealed that SOX-2 was an independent prognostic factor affecting disease-free survival of ICNST(P<0.05). Conclusions: The expression of SOX-2 is closely correlated with occurrence, progression, recurrence and metastasis of ICNST. It may become an important biological marker for evaluating the prognosis of breast cancer and create new ideas for breast cancer research.

Key words: Breast, Invasive carcinoma of no special type, Sex determining region Y-box 2, Clinicopathological features

CLC Number:

R541.7

LU Shuxiong, CHENG Kai, CAI Li, ZHOU Xiaodie, WANG Jianjun, WANG Xuan, SHI Qunli. Expression of SOX-2 in breast invasive carcinoma of no special type and its clinical and pathological significance[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 701-706.

References

[1] Siegel R, Ma J, Zou Z, et al.Cancer statistics, 2014[J]. CA Cancer J Clin,2014,64(1):9-29.
[2] Scaffidi P, Bianchi ME.Spatially precise DNA bending is an essential activity of the sox2 transcription factor[J]. J Biol Chem,2001,276(50):47296-47302.
[3] Hu Q, Friedrich AM, Johnson LV, et al.Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation[J]. Stem Cells,2010,28(11):1981-1991.
[4] Graham V, Khudyakov J, Ellis P, et al.SOX2 functions to maintain neural progenitor identity[J]. Neuron,2003, 39(5):749-765.
[5] 祁洪军, 管冬诗, 魏发强. SOX_2、ER、PR在乳腺癌中的表达及临床意义[J]. 吉林医学,2012,33(17):3604-3605.
[6] 《乳腺癌HER2检测指南》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志,2014,43(4):262-267.
[7] 《乳腺癌雌、孕激素受体免疫组织化学检测指南》编写组. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志,2015(4):237-239.
[8] 张燕平, 李宁, 邓文英, 等. 干细胞标志物SOX-2、β-catenin 表达与胃癌术后复发转移关系[J]. 中国癌症杂志,2014,24(9):684-689.
[9] 姚晋林, 姚孟飞, 窦坤, 等. SOX2和OCT4基因蛋白在乳腺癌中的表达及临床意义的研究[J]. 中国药物与临床,2015,15(5):610-613.
[10] Lengerke C, Fehm T, Kurth R, et al.Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma[J]. BMC Cancer,2011,11:42.
[11] Schaefer T, Wang H, Mir P, et al.Molecular and functional interactions between AKT and SOX2 in breast carcinoma[J]. Oncotarget,2015,6(41):43540-43556.
[12] Gu MJ, Jang BI.Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma[J]. Pathol Oncol Res,2014,20(3):655-660.
[13] 王晓妍, 李志燕, 张薇薇, 等. Nestin和SOX2在皮肤恶性黑色素瘤中的表达及与预后的相关性研究[J]. 华夏医学,2013,26(5):887-890.
[14] 孟垂叶, 王霞, 韩金霞. SOX2、EGFR在乳腺癌组织中的表达及临床意义[J]. 滨州医学院学报,2015,(6):423-425.
[15] Dogan I, Kawabata S, Bergbower E, et al.SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines[J]. Lung Cancer,2014,85(1):1-6.
[16] 李宁, 邓文英, 马懿辉, 等. β-catenin、干细胞标志物Sox-2表达与结肠癌术后复发转移的关系[J]. 中华临床医师杂志: 电子版,2011,5(22):6585-6589.
[17] 赵璐, 宋永波, 张艳苓, 等. Sox2表达与胃肠道肿瘤进展及预后关系的系统回顾[J]. 安徽医学,2017,38(10):1282-1284.
[18] Chen Y, Huang Y, Huang Y, et al.The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis[J]. PLoS One,2013,8(8):e71140.